These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27884075)

  • 1. SRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serum.
    Xie F; Emery MG; Gibbs JP; Rock DA; Rock BM
    Bioanalysis; 2016 Dec; 8(24):2551-2563. PubMed ID: 27884075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 Association With Lipoprotein(a).
    Tavori H; Christian D; Minnier J; Plubell D; Shapiro MD; Yeang C; Giunzioni I; Croyal M; Duell PB; Lambert G; Tsimikas S; Fazio S
    Circ Res; 2016 Jun; 119(1):29-35. PubMed ID: 27121620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.
    Croyal M; Tran TT; Blanchard RH; Le Bail JC; Villard EF; Poirier B; Aguesse A; Billon-Crossouard S; Ramin-Mangata S; Blanchard V; Nativel B; Chemello K; Khantalin I; Thedrez A; Janiak P; Krempf M; Boixel C; Lambert G; Guillot E
    Clin Sci (Lond); 2018 May; 132(10):1075-1083. PubMed ID: 29724769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.
    Gauthier MS; Pérusse JR; Awan Z; Bouchard A; Tessier S; Champagne J; Krastins B; Byram G; Chabot K; Garneau P; Rabasa-Lhoret R; Faubert D; Lopez MF; Seidah NG; Coulombe B
    Methods; 2015 Jun; 81():66-73. PubMed ID: 25770357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
    J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese.
    Yang SH; Li S; Zhang Y; Xu RX; Zhu CG; Guo YL; Wu NQ; Qing P; Gao Y; Cui CJ; Dong Q; Sun J; Li JJ
    J Endocrinol Invest; 2016 Aug; 39(8):875-83. PubMed ID: 26894681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Complex of Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 in the Serum Measured by ELISA.
    Razova OA; Afanas'eva OI; Egiazaryan MG; Sherstyuk EE; Klesareva EA; Pokrovskii SN
    Bull Exp Biol Med; 2020 Sep; 169(5):639-643. PubMed ID: 32979126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
    Chan DC; Wong AT; Pang J; Barrett PH; Watts GF
    Clin Sci (Lond); 2015 Mar; 128(6):379-85. PubMed ID: 25291660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of an aptamer for use as an affinity reagent with MS: PCSK9 as an example protein.
    Gupta V; Lassman ME; McAvoy T; Lee AY; Chappell DL; Laterza OF
    Bioanalysis; 2016 Aug; 8(15):1557-1564. PubMed ID: 27397798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.
    Peng K; Xu K; Liu L; Hendricks R; Delarosa R; Erickson R; Budha N; Leabman M; Song A; Kaur S; Fischer SK
    MAbs; 2014; 6(6):1500-8. PubMed ID: 25484037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 and Lp(a) levels of children born after assisted reproduction technologies.
    Vlachopoulos C; Kosteria I; Sakka S; Gkourogianni A; Terentes-Printzios D; Koutagiar I; Skoumas I; Miliou A; Papassotiriou I; Gardikioti V; Loutradis D; Chrousos G; Kanaka-Gantenbein C; Tousoulis D
    J Assist Reprod Genet; 2019 Jun; 36(6):1091-1099. PubMed ID: 31079266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins.
    Lassman ME; McAvoy T; Lee AY; Chappell D; Wong O; Zhou H; Reyes-Soffer G; Ginsberg HN; Millar JS; Rader DJ; Gutstein DE; Laterza O
    Clin Chem; 2014 Sep; 60(9):1217-24. PubMed ID: 24751376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
    Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
    Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative proteomic analysis of PCSK9 gain of function in human hepatic HuH7 cells.
    Denis N; Palmer-Smith H; Elisma F; Busuttil A; Wright TG; Bou Khalil M; Prat A; Seidah NG; Chrétien M; Mayne J; Figeys D
    J Proteome Res; 2011 Apr; 10(4):2011-26. PubMed ID: 21332221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement.
    Henne KR; Ason B; Howard M; Wang W; Sun J; Higbee J; Tang J; Matsuda KC; Xu R; Zhou L; Chan JC; King C; Piper DE; Ketchem RR; Michaels ML; Jackson SM; Retter MW
    J Pharmacol Exp Ther; 2015 Apr; 353(1):119-31. PubMed ID: 25653417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.